Share
Information on Sartorius Stedim Biotech share (DIM) at a glance
Overview
ISIN | FR0013154002 |
Stock exchange | Euronext Paris |
Market segment | Local Securities - Compartment A (Large Caps) |
Indixes | SBF 120 | CAC All-Tradable | CAC All Shares | CAC Mid & Small 190 | CAC Healthcare | STOXX Europe 600 | MSCI France |
Capital stock | 18,436,038 euros |
Number of shares | 92,180,190 |
- thereof Sartorius AG | 74.3% |
- thereof free float | 25.7% |
Voting rights | ~161.0 million |
- thereof Sartorius AG | 85.0% |
- thereof free float | 15.0% |
Sartorius Stedim Biotech is currently covered by nine sell-side analysts. The following list shows their latest recommandations for Sartorius Stedim Biotech shares.
| Institution | Analyst | Date | Target Price | Recommendation |
J.P. Morgan | Richard Vosser | 11.06.20 | 242.00 | Buy |
UBS | Michael Leuchten | 08.06.20 | 177.00 | Sell |
Morningstar | Aaron Degagne | 28.05.20 | 170.00 | -- |
Société Générale | Delphine Le Louët | 23.04.20 | 216.00 | Hold |
Janney | Paul Knight | 22.04.20 | 300.00 | Hold |
Oddo BHF | Christophe-Raphael Ganet | 28.01.20 | 171.00 | Buy |
Intron Health | Naresh Chouhan | 22.10.19 | 150.00 | Buy |
AlphaValue | Virendra Chauhan | 19.09.19 | 121.00 | Sell |
Gilbert Dupont | Guillaume Cuvillier | 23.10.18 | 119.00 | Sell |
Disclaimer
The analysts’ estimates listed above as examples are not based on research or analyses conducted by Sartorius AG, but rather exclusively on analyses, research, reports, recommendations or ratings of third parties. References to such recommendations and ratings are provided as convenience for readers and for non-binding informational purposes only. These references do not imply that Sartorius AG adopts, endorses or confirms in any way the recommendations, options, opinions, conclusions or estimates of analysts. In particular, analysts’ estimates do not constitute any investment advice given by Sartorius AG. None of the information provided is intended as an offer or encouragement to buy Sartorius shares or other financial instruments, nor is it an offer to purchase or sell.
Sartorius AG shall not assume any liability, in particular for the selection, topicality, quality, completeness or accuracy of the analysts’ estimates shown and, if any, of analysts’ recommendations. Any liability on the part of Sartorius AG for damages or losses incurred by third parties based on the information published on this website shall be excluded.
Sartorius Stedim Biotech strives to enable its shareholders to participate adequately in the company’s success and has continuously increased its dividend in recent years. In line with this objective, we basically follow the policy of paying out a relatively stable share of relevant net profit to our shareholders.
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|---|
| Total dividends paid in millions of € | 20.0 | 30.7 | 38.7 | 42.4 | 52.5 | 62.7 |
| Payout ratio 1 in % | 22.9 | 22.1 | 21.9 | 23.5 | 24.0 | 23.8 |
| Dividend yield 2 in % | 0.8 | 0.6 | 0.7 | 0.8 | 0.7 | 0.5 |
1 Based on the underlying net result 2 Dividends in relation to the corresponding closing prices of the year
“As a consequence of the stock split and the increase of the individual par value of the company's shares, Sartorius Stedim Biotech S.A.’s issued capital amounted to €18.4 million as of December 31, 2018, and was divided into 92,180,190 shares, each with a calculated par value of €0.20. As some of the shares convey double voting rights, there were a total of 161,024,614 voting rights as of the reporting date.
As of December 31, 2018, Sartorius AG holds 74.3% of the share capital and 85.0% of the outstanding voting rights. The remaining 25.7% of the shares are in free float; corresponding to 15.0% of the outstanding voting rights.”